Altium Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Altium Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-850,000	Closed	-$3.57M	–	109
2023 Q1	$3.57M	Buy	850,000 +400,000	+89%	+$2.08M	1.98%	18
2022 Q4	$2.7M	Buy	450,000 +23,000	+5%	+$126K	1.37%	29
2022 Q3	$2.48M	Buy	+427,000	New	+$2.66M	0.91%	43
2022 Q2	–	Sell	-299,800	Closed	-$1.4M	–	147
2022 Q1	$1.4M	Sell	299,800 -1,885,200	-86%	-$5.62M	0.47%	68
2021 Q4	$5.42M	Sell	2,185,000 -1,128,000	-34%	-$2.76M	1.49%	18
2021 Q3	$9.77M	Sell	3,313,000 -365,677	-10%	-$996K	2.56%	4
2021 Q2	$9.2M	Buy	3,678,677 +3,089,685	+525%	+$7.41M	2.13%	6
2021 Q1	$1.71M	Hold	588,992	–	–	0.48%	88
2020 Q4	$1.9M	Buy	+588,992	New	+$1.96M	0.71%	67

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Altium Capital Management's CTIC Position: Q2 2023 in Review

Altium Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 850,000 shares — an estimated $3.57M sold.

Altium Capital Management first reported a position in CTIC in Q4 2020 and held it in 9 quarters. The position peaked at $9.77M in Q3 2021. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Altium Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Altium Capital Management sold 850,000 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $3.57M.
Altium Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2020 and held it in 9 quarters.
Altium Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $9.77M in Q3 2021.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Altium Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.